ArticleInfection and immunity2009
The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Evaluation of immune responses toFrontiers in veterinary science · 2022Pooled it
- Comparative production of recombinant capripoxvirus in Vero cells using microcarrier- and macrocarrier-based dynamic cell culture systems under serum-free conditions.Applied microbiology and biotechnology · 2026Article
- Brucellosis vaccine development: immunological mechanisms, animal models, and future directions.Archives of microbiology · 2026Review
- A novel loop-mediated isothermal amplification assay coupled with lateral flow assay for differential detection of Brucella spp from Brucella abortus S19 vaccine strain.Veterinary research communications · 2026Article
- The atypical quorum sensing system of classicalJournal of bacteriology · 2025Review
- Quorum sensing LuxR proteins VjbR and BabR jointly regulateJournal of bacteriology · 2025Article
- Preparation and application of aFrontiers in immunology · 2024Article
- A novelVirulence · 2023Article
- Brucellae as resilient intracellular pathogens: epidemiology, host-pathogen interaction, recent genomics and proteomics approaches, and future perspectives.Frontiers in veterinary science · 2023Review
- Application of encapsulated nano materials as feed additive in livestock and poultry: a review.Veterinary research communications · 2022Review
- Combined immunization with inactivated vaccine reduces the dose of live B. abortus A19 vaccine.BMC veterinary research · 2022Article
- Alginate microencapsulation of an attenuated O-antigen mutant of Francisella tularensis LVS as a model for a vaccine delivery vehicle.PloS one · 2022Article
- Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16MΔvjbR strain in goats.Vaccine · 2021Article
- Brucella abortus and Pregnancy in Mice: Impact of Chronic Infection on Fertility and the Role of Regulatory T Cells in Tissue Colonization.Infection and immunity · 2020Article
- A Novel, Rapid, and Simple PMA-qPCR Method for Detection and Counting of ViableJournal of veterinary research · 2020Article
- Article
- Vaccine Candidate Brucella melitensis 16MmSphere · 2020Article
- Interaction of Brucella abortus with Osteoclasts: a Step toward Understanding Osteoarticular Brucellosis and Vaccine Safety.Infection and immunity · 2020Article
- Article
- Vaccine safety studies ofVaccine: X · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucellosis is an important zoonotic disease of nearly worldwide distribution. Despite the availability of live vaccine strains for bovine (S19, RB51) and small ruminants (Rev-1), these vaccines have several drawbacks, including residual virulence for animals and humans. Safe and efficacious immunization systems are therefore needed to overcome these disadvantages. A vjbR knockout was generated in the S19 vaccine and investigated for its potential use as an improved vaccine candidate. Vaccination with a sustained-release vehicle to enhance vaccination efficacy was evaluated utilizing the live S19 DeltavjbR::Kan in encapsulated alginate microspheres containing a nonimmunogenic eggshell precursor protein of the parasite Fasciola hepatica (vitelline protein B). BALB/c mice were immunized intraperitoneally with either encapsulated or nonencapsulated S19 DeltavjbR::Kan at a dose of 1 x 10(5) CFU per animal to evaluate immunogenicity, safety, and protective efficacy. Humoral responses postvaccination indicate that the vaccine candidate was able to elicit an anti-Brucella-specific immunoglobulin G response even when the vaccine was administered in an encapsulated format. The safety was revealed by the absence of splenomegaly in mice that were inoculated with the mutant. Finally, a single dose with the encapsulated mutant conferred higher levels of protection compared to the nonencapsulated vaccine. These results suggest that S19 DeltavjbR::Kan is safer than S19, induces protection in mice, and should be considered as a vaccine candidate when administered in a sustained-release manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.